Xiao Ke Qing improves glycometabolism and ameliorates insulin resistance by regulating the PI3K/Akt pathway in KKAy mice.
10.1007/s11684-018-0662-8
- Author:
Xiaoqing LI
1
;
Xinxin LI
2
;
Genbei WANG
1
;
Yan XU
1
;
Yuanyuan WANG
1
;
Ruijia HAO
1
;
Xiaohui MA
1
Author Information
1. Department of Pharmacology and Toxicology, Tasly Pharmaceutical Co., Ltd., Tianjin, 300410, China.
2. Department of Pharmacology and Toxicology, Tasly Pharmaceutical Co., Ltd., Tianjin, 300410, China. lixx@tasly.com.
- Publication Type:Journal Article
- Keywords:
KKAy mice;
PI3K/Akt pathway;
XKQ;
diabetic liver disease;
type 2 diabetes mellitus
- MeSH:
Animals;
Blood Glucose;
drug effects;
metabolism;
Diabetes Mellitus, Type 2;
drug therapy;
metabolism;
Disease Models, Animal;
Drugs, Chinese Herbal;
pharmacology;
Female;
Glucose Tolerance Test;
Glucose Transporter Type 4;
metabolism;
Hypoglycemic Agents;
pharmacology;
Insulin;
blood;
Insulin Resistance;
Liver;
drug effects;
pathology;
Mice;
Mice, Inbred C57BL;
Phosphatidylinositol 3-Kinases;
metabolism;
Proto-Oncogene Proteins c-akt;
metabolism;
Signal Transduction;
drug effects
- From:
Frontiers of Medicine
2018;12(6):688-696
- CountryChina
- Language:English
-
Abstract:
Xiao Ke Qing (XKQ) granule has been clinically used to treat type 2 diabetes mellitus (T2DM) for 10 years in Chinese traditional medication. However, its mechanisms against hyperglycemia remain poorly understood. This study aims to investigate XKQ mechanisms on diabetes and diabetic liver disease by using the KKAy mice model. Our results indicate that XKQ can significantly reduce food and water intake. XKQ treatment also remarkably decreases both the fasting blood glucose and blood glucose in the oral glucose tolerance test. Additionally, XKQ can significantly decrease the serum alanine aminotransferase level and liver index and can alleviate the fat degeneration in liver tissues. Moreover, XKQ can ameliorate insulin resistance and upregulate the expression of IRS-1, PI3K (p85), p-Akt, and GLUT4 in the skeletal muscle of KKAy mice. XKQ is an effective drug for T2DM by ameliorating insulin resistance and regulating the PI3K/Akt signaling pathway in the skeletal muscle.
